BioCentury
ARTICLE | Clinical News

Apra: Phase II

May 30, 2000 7:00 AM UTC

Among 28 evaluable patients in CTIC’s ongoing 80-patient Phase II trial, 1 patient has had a partial response and 4 had stable disease. Side effects included hematuria and fatigue. Data were presented...